Tiziana Life Sciences
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 9
- Market Cap
- $125.8M
- Introduction
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 55
- Registration Number
- NCT06890923
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
- Conditions
- SafetyTolerability
- Interventions
- Drug: Foralumab NasalDrug: Placebo
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 27
- Registration Number
- NCT06879067
- Locations
- 🇺🇸
Ann Romney Center for Neurologic Diseases, Boston, Massachusetts, United States
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- Conditions
- Non-Active Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT06802328
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06292923
- Locations
- 🇺🇸
Yale, North Haven, Connecticut, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Milciclib in Combination With Gemcitabine in Advanced NSCLC
- Conditions
- NSCLC
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 28
- Registration Number
- NCT05651269
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05028946
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
- Conditions
- Primary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisMultiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05029609
In-patient COVID-19 Study of Intranasal Foralumab
- Conditions
- COVID-19 Lower Respiratory InfectionCovid19COVID-19 Respiratory Infection
- Interventions
- Other: Placebo
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT04983446
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
- Conditions
- NAFLDNASH - Nonalcoholic SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT03291249
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 31
- Registration Number
- NCT03109886
- Locations
- 🇬🇷
Ippokrateio General Hospital of Athens, Athens, Greece
🇬🇷Laiko General Hospital of Athens, Athens, Greece
🇬🇷General University Hospital of Larissa, Larissa, Greece